LMR Partners’s Eikon Therapeutics EIKN Stock Holding History

LMR Partners’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-115,000	Closed	-$1.22M	–	1909
2026 Q1	$1.22M	Buy	+115,000	New	+$1.54M	﹤0.01%	944

Other funds holding EIKN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

LMR Partners's EIKN Position: Q2 2026 in Review

LMR Partners sold out of Eikon Therapeutics (EIKN) in Q2 2026, closing a stake of 115,000 shares — an estimated $1.22M sold.

LMR Partners first reported a position in EIKN in Q1 2026 and held it in 1 quarter. The position peaked at $1.22M in Q1 2026. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

LMR Partners reported no remaining Eikon Therapeutics position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 115,000 Eikon Therapeutics shares in Q2 2026, an estimated $1.22M.
LMR Partners first reported a position in Eikon Therapeutics in Q1 2026 and held it in 1 quarter.
LMR Partners's Eikon Therapeutics position peaked at $1.22M in Q1 2026.
70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.